• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Upstream Bio To Unveil Phase 2 Verekitug Data At ATS 2026

    FIRSTWORD PHARMA

    Upstream Bio Shares Verekitug Ph3 Plan, FY25 Results

    GLOBENEWSWIRE

    Upstream Bio Unveils Verekitug Phase 2 VIBRANT Trial Data

    GLOBENEWSWIRE

    Upstream Bio Presents VIBRANT CRSwNP Data at AAAAI 2026

    GLOBENEWSWIRE

    Upstream Posts Tezspire-like Asthma Efficacy in phase 2

    FIERCE BIOTECH

    Upstream Bio To Webcast Phase 2 VALIANT Trial Results

    GLOBENEWSWIRE

    Upstream Bio Reveals Q3 2025 Financial Results, Shows Ongoing

    GLOBENEWSWIRE

    Upstream Bio To Join November Investor Conferences

    GLOBENEWSWIRE

    Upstream Bio Reveals Verekitug`s Strong Pharmacodynamic Activity

    GLOBENEWSWIRE

    Upstream Bio Joins Stifel 2025 Virtual Immunology Forum

    GLOBENEWSWIRE

    Upstream Bio`s Phase 2 Trial Shows Promise for CRSwNP Treatment

    GLOBENEWSWIRE

    Upstream Posts Phase 2 Sinusitis Win

    FIERCE BIOTECH

    Upstream Bio to Report Phase 2 Verekitug Data for CRSwNP Trial

    GLOBENEWSWIRE

    Verekitug, a Novel Antibody Antagonist, Shows Potent Mechanism

    GLOBENEWSWIRE

    Upstream Bio to Present Verekitug TSLP Data at EAACI 2025

    GLOBENEWSWIRE

    Upstream Bio Appoints Allison Ambrose as General Counsel

    GLOBENEWSWIRE

    Upstream Bio Announces Closing of $293 Million Upsized IPO

    GLOBENEWSWIRE

    Upstream Bio, two other US biotech startups price IPOs

    REUTERS

    Upstream Bio Announces Pricing of Upsized Initial Public Offering

    GLOBENEWSWIRE

    CAMP4 is latest to eye IPO, while Upstream spells out $182M plan

    FIERCE BIOTECH

    Upstream Plans IPO For Inflammation-Focused Research

    FIERCE BIOTECH

    Upstream Bio Presents Verekitug Asthma Dose Ranging At ATS

    GLOBENEWSWIRE

    Upstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101)

    BUSINESSWIRE

    Upstream Bio Announces Dosing of First Patients in Phase 2 Trial of Verekitug

    BUSINESSWIRE

    Upstream Bio Announces $200M Series B Financing to Advance UPB-101

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.